Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Veritone Inc (VERI) vs GeneDx Holdings Corp (WGS) Price & Performance

Veritone IncTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Veritone Inc vs GeneDx Holdings Corp — how do they compare? Veritone Inc trades at $1.49 (market cap $138.04M), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: GeneDx Holdings Corp is far larger — about 17.7× Veritone Inc's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.

VERIWGS
Market Cap
$138.04M$2.44B
Sector
TechnologyTechnology
52-Week High
$8.39$167.51
52-Week Low
$1.00$34.51
Enterprise Value
$170.07M$2.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Veritone Inc

Veritone (VERI) trades at $1.53, up 6.25% in 24 hours, with a bullish technical signal from moving averages and ADX indicators. The company reported revenue of $92.19M in 2025 but a net loss of $111.73M, reflecting negative profit margins and ROE. Recent news highlights partnerships with ZeroEyes and the Department of Energy, though a securities class action lawsuit was filed in July 2026 over alleged accounting issues.

The outlook is mixed: analyst consensus leans neutral with 46% buy ratings, but persistent losses and legal risks pose challenges. Upside hinges on AI partnership growth improving profitability, while downside risks include ongoing cash burn and litigation uncertainties. Investors should weigh growth potential against financial stability concerns.

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.

Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.

Returns comparison

Trailing returns across standard periods

About Veritone Inc

Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.

Read more on VERI

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS